Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.52 |
| ▸ | RARB | P10826 | 13/20 | 0.51 |
| ▸ | RARG | P13631 | 13/20 | 0.51 |
| ▸ | RARA | P10276 | 11/20 | 0.51 |
| ▸ | RXRB | P28702 | 7/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.45 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157965 | 1.00 | RXRA (0.52) | RXRARARBRARGRARARXRB | |
| SCHEMBL8681351 | 0.80 | RXRA (0.56) | RXRARARBRARGRARARXRB | |
| SCHEMBL7714824 | 0.80 | CYP26A1 (0.51) | RXRARARBRARGRARARXRB | |
| SCHEMBL7715218 | 0.79 | RARB (0.42) | RXRARARBRARGRARARXRB | |
| SCHEMBL7715340 | 0.79 | RXRA (0.35) | RXRARARBRARGRARARXRB | |
| SCHEMBL3541162 | 0.79 | RXRA (0.58) | RXRARARBRARGRARARXRB | |
| SCHEMBL7717634 | 0.78 | RXRA (0.48) | RXRARARBRARGRARARXRB | |
| SCHEMBL1406406 | 0.75 | RXRA (0.36) | RXRARARBRARGRARARXRB | |
| SCHEMBL7713056 | 0.75 | RARB (0.46) | RXRARARBRARGRARARXRB | |
| Methyl Alcohol SCHEMBL7715082 | 0.75 | RXRA (0.48) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878842-B2 | Process for the enantioselective synthesis of propargyl alcohol derivatives of R configuration from the racemic mixtures thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-04-12 | — | — | US | disclosed |
| EP-1501780-A1 | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF PROPARGYL ALCOHOL DERIVATIVES OF R CONFIGURATION FROM THE RACEMIC MIXTURES THEREOF | Galderma Research & Development, S.N.C. (FR) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004032914-A2 | USE OF A PROPARGYL ALCOHOL ENANTIOMER FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-04-22 | — | — | WO | disclosed |
| US-20040049067-A1 | Process for the enantioselective synthesis of propargyl alcohol derivatives of R configuration from the racemic mixtures thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-03-11 | — | — | US | disclosed |
| WO-2003091196-A1 | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF PROPARGYL ALCOHOL DERIVATIVES OF R CONFIGURATION FROM THE RACEMIC MIXTURES THEREOF | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049067-A1 | Process for the enantioselective synthesis of propargyl alcohol derivatives of R configuration from the racemic mixtures thereof | ADH1A, ADH5, ADH1C | RXRA 898/4885RARB 547/4885RARG 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.